Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective : introduction of a new treatment to the patient journey. A simulation of three European countries by Marcellusi, A. et al.
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of 
Pharmacoeconomics and Outcomes Research on 04/02/19, available online: https://www.tandfonline.com/doi/
full/10.1080/14737167.2019.1569516
1 | P a g e  
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections 
(ABSSSIs) from the national payer perspective: introduction of a new treatment to the 
patient journey. A simulation of 3 European Countries 
 
ABSTRACT 
Background: The aim of this study was to develop a spending predictor model to evaluate 
the direct costs associated with the management of ABSSSIs from the National healthcare 
provider’s perspective of Italy, Romania and Spain.  
Methodology: A decision-analytic model was developed to evaluate the diagnostic and 
clinical pathways of hospitalized ABSSSI patients based on scientific guidelines and real-
world data. A Standard of Care (SoC) scenario was compared with a dalbavancin scenario in 
which the patients could be discharged early. The epidemiological and cost parameters 
were extrapolated from national administrative databases (i.e., hospital information 
system). A probabilistic sensitivity analysis (PSA) and one-way sensitivity analysis (OWA) 
were performed. 
Results: Overall, the model estimated an average annual number of patients with ABSSSIs of 
approximately 50,000 in Italy, Spain and Romania. On average, the introduction of 
dalbavancin reduced the length of stay by 3.3 days per ABSSSI patient. From an economic 
perspective, dalbavancin did not incur any additional cost from the NHS perspective, and 
the results were consistent among the countries. The PSA and OWA demonstrated the 
robustness of these results. 
Conclusion: This model represents a useful tool for policymakers by providing information 
regarding the economic and organisational consequences of an early discharge approach in 
ABSSSI management. 
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Key point:  
1. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) impose a significant 
economic burden on the healthcare systems due to the associated inpatient 
management, surgical procedures and parenteral antibiotic therapy. 
2. The present study aimed to develop a predictor model to evaluate the direct costs 
associated with the management of ABSSSIs. We collected data of hospital 
management in three European countries, namely, Italy, Romania and Spain and 
compared drug costs related to therapy-related adverse events, administration 
costs, diagnosis-related groups (DRG) and service-related resources associated with 
standard of care (SoC) and dalbavancin. 
3. the introduction of dalbavancin reduced the length of stay by 3.3 days per ABSSSI 
patient and from an economic perspective, dalbavancin did not incur in any 
additional cost from the NHS perspective of all the included countries. Considering 
the costs from a hospital perspective according to the probabilistic analysis, 
dalbavancin could decrease the total economic burden with a significant difference. 
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INTRODUCTION 
In 2013, the US Food and Drug Administration (FDA) coined the acronym “ABSSSIs” 
(Acute Bacterial Skin and Skin Structure Infections) to include all complicated infections of 
the skin and soft tissues [1]. ABSSSIs include severe skin and soft tissue infections, such as 
cellulitis, erysipelas, cutaneous abscesses, infected wounds and ulcers, that usually require 
inpatient management, surgical procedures and parenteral antibiotic therapy.  
Inpatient treatment of ABSSSIs imposes a significant economic burden on the 
healthcare system. In the United States, over 750,000 patients per year are admitted to the 
hospital for ABSSSI, incurring an estimated cost of >6 billion dollars [2]. Nearly 10 % of all US 
hospital admissions are attributed to ABSSSIs[3], while in Europe ABSSSIs may account up to 
15% of all infections treated in hospitals [4].   
ABSSSIs are primarily caused by Gram-positive pathogens, mainly Staphylococcus 
aureus and Streptococcus pyogenes, but are also caused by Gram-negative and anaerobic 
bacteria, particularly in polymicrobial infections [5]. 
S. aureus has historically been the leading cause of ABSSSIs, although its clinical 
relevance has rapidly increased over the previous 15 years due to the emergence of 
methicillin-resistant S. aureus (MRSA) [6]. S. aureus is considered the predominant pathogen 
in all regions across North America, Latin America and Europe. The rates of MRSA vary 
among these continents, and the highest proportion is observed in the Americas [6-8]. 
Staphylococcus aureus is also the most common cause of complicated Skin and Soft Tissue 
infections (cSSTIs) in Europe. According to a study investigating more than 3000 cSSTI-
associated isolates sampled from 19 countries in and around Europe between 2008 and 
2009, nearly one-third of the isolates were S. aureus, and of these isolates, approximately 
one-half were MRSA [7, 8]. 
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In Europe, the incidence of MRSA has changed over the previous 10 years; however, 
in the European Community, MRSA accounts for 16.7% of all Staphylococcus aureus isolates. 
In ten countries, the incidence of MRSA in infections sustained by Staphylococcus aureus 
was 10-25%. Although, an incidence of MRSA >25% was reported in Italy and Spain, and 
accounted almost for 50% of S. aureus isolates in Romania [9].  
Due to the emerging incidence of bacterial resistance to multiple antibiotics, ABSSSIs 
are increasingly challenging to treat [10]. Furthermore, the choice of treatment is often 
complicated by the urgency to treat with an antibiotic therapy before having obtained a 
confirmed microbiological diagnosis. 
Due to the increasing incidence of MRSA, particularly in community-acquired 
infections, vancomycin, which is the standard therapy for documented MRSA infections, is 
often the treatment of choice if MRSA is suspected. However, the use of this agent is 
associated with suboptimal outcomes [11-13].  
The guidelines of the Infectious Diseases Society of America recommend therapy 
with β-lactam or clindamycin for mild/moderate ABSSSIs and non-purulent ABSSSI and 
vancomycin plus piperacillin/tazobactam for severe, non-purulent ABSSSI [5]. The empirical 
treatment of purulent ABSSSIs should cover MRSA with doxycycline or 
trimethoprim/sulfamethoxazole (TMP/SMX) in moderate cases and vancomycin, 
daptomycin, linezolid, telavancin, or ceftaroline in severe cases [14]. However, clinical MRSA 
isolates have progressively shown a decreasing susceptibility or resistance to these drugs 
[15]. Consequently, the treatment of ABSSSIs currently requires a greater need for 
hospitalization, which is associated with a net increase in costs [16]. 
Dalbavancin is a novel long-acting lipoglycopeptide that was approved by the FDA in 
May 2014 and the European Medicines Agency (EMA) in February 2015 for the treatment of 
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ABSSSIs caused by susceptible Gram-positive organisms. It is active against gram-positive 
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and minimum 
inhibitory concentrations (MICs) are consistently <0.125 µg/ml, lower than most other anti-
MRSA agents. In vitro data against MRSA, suggest that dalbavancin is 4–8 times more potent 
than vancomycin. Moreover, dalbavancin has  a   β  half-life (elimination half life ) of  >8  
days  (~200  hours)  and  a  terminal  half-life  of  >14  days  (~346  hours),  allowing for  
clinical  safety  and  efficacy  assessment  using  a once-weekly dosing regimen of 1000 mg 
on day1  and  500  mg  on  day  8 [17, 18]. 
Due to its long-acting bactericidal activity and unique dosing schedule, dalbavancin 
allows clinicians to endorse early discharge (ED) programmes, enabling patients to complete 
the treatment after hospital discharge. ED programmes have been shown to significantly 
reduce the use of hospital resources [19] in the management of MRSA infections, 
particularly complicated skin and skin structure infections [19, 20].  
The first objective of this study was to develop a spending predictor model to 
evaluate the direct costs associated with the hospital management of ABSSSIs from the 
perspective of the National Health Service (NHS). The second objective was to collect data of 
the direct costs of hospital management of ABSSSIs in three European countries, namely, 
Italy, Romania and Spain. Finally, the third objective was to apply country-specific cost 
inputs to the spending predictor model to compare the estimated direct costs of the 
hospital treatment of ABSSSIs between patients treated with standard antibiotics therapy 
and those treated with dalbavancin. 
 
METHODS 
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Authors followed methodological indications of the ISPOR Budget Impact Analysis—Principles 
of Good Practice [21]. Due to the lack of data availability and as advised by the above-
mentioned article, whenever data from the clinical trials and/or the official administrative 
databases were not accessible, clinical experts’ opinions were used as data source [21]. 
Health care systems and perspective 
A decision-analytic model was built based on the current clinical practices in three 
European countries to simulate the hospital management of ABSSSI patients receiving 
empiric treatment with antibiotics (Figure 1).  
The choice of the countries was based on access to healthcare and public spending 
per capita data. Most of 28 Countries in the European Community have a publicly directly or 
indirectly funded National system that provides universal access to healthcare. However, 
national expenditures on healthcare widely vary around the EU28 mean value (€ 2,323 per 
capita) [22]. Based on the relevance of incremental costs/savings to the public budget, the 
simulation included the two EU25 countries closest to the mean (Italy, € 2,339, and Spain, € 
2,199) and the country with the lowest per capita annual expenditure (Romania, € 809).  
The model was generated from the perspective of the National healthcare provider.  
 
Eligible population 
An algorithm consistent with the IDSA guidelines published in 2014 [14] was used to 
identify severe purulent and non-purulent patients requiring observation for over 72 hours. 
The eligible patients were identified using the national administrative databases of each 
country (Appendix A). The algorithm included all acute inpatient admissions. The longest 
data collection period per country was selected based on the available data as follows: 
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between January 1, 2006 and December 31, 2010 in Italy, January 1, 2010 and December 31, 
2013 in Romania, and January 1, 2006 and December 31, 2015 in Spain.  
 
Intervention comparison and model structure 
The decisional tree was designed to follow IDSA guidelines and as illustrated in 
Figure 1: in the model, all ABSSSI patients can be hospitalized for purulent or non-purulent 
ABSSSIs (first probabilistic node). The patients initially received an empirical antibiotic 
treatment to cover both Gram-positive and Gram-negative infections.  
The model considers that the patients could receive vancomycin, intravenous 
linezolid or teicoplanin as Gram-positive therapy plus piperacillin tazobactam as Gram-
negative therapy (current intervention or Standard of Care, SoC) or the new intervention of 
dalbavancin as the Gram-positive therapy of choice in addition to piperacillin tazobactam. 
The choice of antibiotic combination therapy (antibiotic for gram-positive plus piperacillin 
tazobactam)  was made according to the IDSA guidelines on the treatment of severe ABSSIs 
[5].   
After receiving the first dose of the empirical antibiotic therapy, the patients may 
progress to one of the following treatment pathways (branch of possible events): purulent 
surgical eligible for early discharge (ED), purulent surgical not eligible for ED, purulent not 
surgical, non-purulent Gram-positive, non-purulent Gram-negative, non-purulent 
indeterminate or polymicrobial. Each pathway (except for purulent surgical not eligible for 
ED) includes the following states: discharge on day 4, observation up to day 8, discharge on 
day 9, or observation up to the clinical evaluation. The transition probabilities change 
according with the treatment (SoC or dalbavancin) administered on day 0 (tree’s decision 
node).  
8 | P a g e  
 
Non-monetary inputs to the model 
The input value of the probabilistic nodes is reported in Table 1. 
The purulent and non-purulent occurrence rates and the time to discharge in the 
SoC scenario were estimated based on data obtained from the real-world databases of each 
country (details are provided in Appendix), while the discharge probabilities in the 
dalbavancin scenario were estimated based on the opinion consensus of experts (co-author 
of this work). However, the transition probabilities in Spain were assumed to be the same as 
those applied to Italy due to the lack of country-specific data. 
The cut-offs for the eligibility to early discharge (ED) were set based on the 
distribution of the length of stay of the included patients stratified as purulent or non-
purulent. For both purulent and non-purulent infections, eligibility for early discharge was 
attributed to patients with a length of stay >4, considering the differences in medical 
treatments as suggested by clinical experts.  
All purulent infections were considered sustained by S. aureus, while the distribution 
of the bacteria responsible of the non-purulent infections was estimated based on the 
consensus among the experts. The treatment undergone by patients with purulent and non-
purulent infections and the discharge probabilities in the SoC scenario were based on real-
world data obtained from the administrative databases of each Country. For the sake of 
avoiding an overcomplication of the decisional tree, all the therapies included in the model 
were assumed to have 100% efficacy.  
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Table 1 - Transition probabilities: SoC (real-world data) vs. Dalbavancin (expert opinion)  
Number of patients with ABSSSIs ITALY ROMANIA SPAIN References 
Non-purulent patients - Sort of bacteria Model value  
Indeterminate 71% 18% 70% 
Expert opinion 
Polymicrobial 17% 18% 10% 
Gram-negative 7% 9% 7% 
Gram-positive 6% 56% 13% 
Purulent patients - Sort of origin Model value  
Surgical 26% 95% 70% 
Expert opinion 
Non-surgical 74% 5% 30% 
Surgical eligible for ED 50% 30% 50% 
Surgical not eligible for ED 50% 70% 50% 
Discharge distribution with dalbavancin 
   
References 
Non-purulent patients: Indeterminate or polymicrobial Model value  
Discharge (4 day) 50% 60% 60% 
Expert opinion 
Discharge (8 day) 70% 70% 70% 
 Non-purulent patients: Gram-positive Model value  
Discharge (4 day) 70% 70% 70% 
Expert opinion 
Discharge (8 day) 80% 90% 90% 
Purulent patients: Surgical Model value  
Discharge (4 day) 70% 70% 50% 
Expert opinion 
Discharge (8 day) 80% 80% 70% 
Purulent patients: Non-surgical Model value  
Discharge (4 day) 70% 65% 40% 
Expert opinion 
Discharge (8 day) 80% 80% 70% 
Discharge distribution with standard therapy 
   
References 
Non-purulent patients: Indeterminate or polymicrobial Model value  
Discharge (4 day) 11% 10% 11% Data from administrative 
databases Discharge (8 day) 42% 35% 42% 
Non-purulent patients: Gram-positive Model value  
Discharge (4 day) 11% 31% 11% Data from administrative 
databases Discharge (8 day) 58% 55% 58% 
Purulent patients: Surgical Model value  
Discharge (4 day) 11% 55% 11% Data from administrative 
databases Discharge (8 day) 50% 65% 50% 
Purulent patients: Non-surgical Model value  
Discharge (4 day) 12% 33% 12% Data from administrative 
databases Discharge (8 day) 57% 67% 57% 
* in the table are shown the percentage of discharge at each decision point of the analytic model that has 
been used to describe patients’ pathway. Each pathway (except for purulent surgical not eligible for ED) 
includes the following states: discharge on day 4, observation up to day 8, discharge on day 9, or observation 
up to the clinical evaluation. Full distribution is shown in appendix B in table 2. 
 
Cost inputs to the model 
The inputs used to inform the model were based on a literature review and expert 
clinical opinion [23]. The following cost assumptions were used to inform the model based 
on a consensus of expert opinion.  
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 Hospitalization cost: Consistent with the perspective of the study, the 
hospitalization costs were determined exclusively based on National Diagnosis-
Related Group (DRG) tariffs. Consequently, from the perspective of the payer, the 
patient’s length of stay (LoS) at a hospital is irrelevant to the cost of hospitalization. 
However, a length of stay >8 days implies additional risks to the patient, which could 
bear incremental costs to the payer as follows: 
− Additional risks: The model assumes that if a patient is not discharged by day 
8, an increased possibility of adverse events is associated with the length of 
hospital stay. 
− Incremental costs: The incremental costs were estimated as the difference 
between the direct costs associated with a patient LoS <9 days and the cost 
incurred by patients with a LoS ≥9 days. 
 A systematic review of the existent literature was performed to identify the direct 
costs associated with each state of the model. Table 2 shows the inputs used to 
inform the cost estimate of each intervention. Consistent to Summary of Product 
Characteristics (SmPC) of each medicament included in the analysis and clinical 
practice, all the costs relative to treatments’ adverse events were considered not 
sensitive, with the only exception of the renal adverse event concomitant to 
vancomycin administration that requires a medical treatment in addition of 
therapy’s withdrawal. The inputs used to evaluate the additional costs incurred with 
vancomycin are summarized in Appendix B. 
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Table 2 – Costs inputs for each country included in the analysis 
Drug therapy ITALY ROMANIA SPAIN 
References 
 Italy Romania Spain 
Dalbavancin (1+1 dose) € 773 € 670* € 844       
Dalbavancin (3 doses) € 387 € 335* € 422       
Vancomycin (daily cost of administration) € 19 € 23 € 14 [24]  [25]  [26] 
Teicoplanin (daily cost of administration) € 45 € 24 € 22       
Linezolid (daily cost of administration) € 76 € 50 € 72       
% who received vancomycin 35% 59% 54% 
Expert opinion Expert opinion Expert opinion % who received teicoplanin 35% 11% 7% 
% who received linezolid 30% 30% 39% 
Gram-positive therapy (daily administration) € 45 € 31 € 37       
Piperacillin tazobactam  € 23 € 26 € 5 [24]  [25]  [26] 
Oral therapy (Amoxicillin Clavulanate) € 5 € 3 € 3       
Hospitalization          
Incremental cost due to an average length of hospital 
stay >9 days (purulent) 
€ 884 € 310 € 884 Data from 
administrative 
databases 
Data from 
administrative 
databases 
Assumed to be 
equal to Italy Incremental cost due to an average length of hospital 
stay >9 days (non-purulent) 
€ 870 € 654 € 870 
Diagnostic tests          
Swab € 8.80 € 3 € 7  
[27] 
 
 
Database from 
The National 
Institute for 
Infectious 
Diseases Prof. dr. 
Matei Bals 
 
[28] 
 
 
Ultrasound € 50 € 6 € 20 
CAT € 48 € 40 € 86 
MRI € 160 € 156 € 126 
Specialist service          
Examination € 21 € 5 € 37 [27] 
Database from 
The National 
Institute for 
Infectious 
Diseases Prof. dr. 
Matei Bals 
[28] 
Placement of PICC and other related costs          
Placement of peripherally inserted central catheter 
(PICC) 
€ 383 € 267 € 495 [29] Database from 
The National 
Institute for 
Infectious 
Diseases Prof. dr. 
Matei Bals 
[28] 
Thrombophlebitis € 306 € 960 € 498 [29] [28] 
Malposition € 236 € 134 € 248 [29] [28] 
Malfunction  € 383 € 267 € 495 [29] [28] 
PICC-related infection € 1,263 € 1,038 € 945 
Difference 
between DRG 277 
(with CC) and 
DRG 278 (without 
CC) 
Difference 
between DRG 277 
(with CC) and 
DRG 278 (without 
CC) 
Difference 
between DRG 277 
(with CC) and 
DRG 278 (without 
CC) 
PICC dressing patch costs € 6 € 10 € 7 Appendix B Appendix B Appendix B 
Additional costs due to vancomycin          
EA dialysis  € 6 € 19 € 13      
EA nephrotoxicity € 1 € 3 € 4 Appendix B Appendix B Appendix B 
Monitoring  € 50 € 46 € 185       
PICC Risk          
Risk of thrombophlebitis (daily) 0.8% 0.8% 0.8% 
[30] 
 
[30] 
 
 
[30] 
 
Risk of infection (daily) 0.2% 0.2% 0.2% 
Risk of malposition 9.3% 9.3% 9.3% 
Risk of malfunction (daily) 0.8% 0.8% 0.8% 
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* Estimated cost 
 
 
Statistical analysis 
The results are presented as the net difference between the direct costs incurred by 
the SoC treatment and those incurred by the dalbavancin treatment. 
A probabilistic sensitivity analysis (PSA) and one-way deterministic sensitivity 
analysis (OSA) were performed to estimate the intrinsic variability in the inputs used to 
inform the model. 
The probabilistic distribution used for the PSA was obtained by applying generally 
reported development of economic evaluation models and distinguishing between costs 
(gamma distribution) and epidemiological parameters (beta distribution) [31]; the details 
are provided in Appendix B.  
In total, 5,000 Monte Carlo simulations were performed. 
The uncertainty imposed by the inputs on the results of the analysis was estimated 
by performing a OSA. In this analysis, the inputs varied within an uncertainty range, and the 
impact on the final result was represented by a tornado graph. 
In particular, the impact of the variation in the following parameters was analysed: 
1. Efficiency of dalbavancin (-10% to +10%) - representing the efficacy on early 
discharging compared to the SoC; 
2. Frequency of adverse events (-10% to +10%); 
3. Additional hospitalization cost (-10% to +10%); 
4. Administration cost (PICC) (-10% to +10%); 
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5. Daily cost in the hospital (€ 0-Max), where the maximum is equal to € 732 in the 
Italian NHS [32],€ 601 Spanish NHS [33] and € 100 in the Romanian NHS [25]; and 
6. Length of stay (LoS) (-10% to +10%). 
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RESULTS 
The model included approximately 50,000 patients admitted annually with a main 
diagnosis of ABSSSI in Italy, Romania and Spain. Figure 2 shows the number and 
stratification by state of the ABSSSI patients in each country. In Italy, 19,034 patients were 
included in the analysis as follows: 79.5% (15,131) of the patients were affected by severe 
ABSSSIs, 54% of the patients had a diagnosis of non-purulent ABSSSIs and 46% of the 
patients had a diagnosis of purulent ABSSSIs. The average age of the patients with non-
purulent ABSSSIs was 63.8 years, and that of the purulent ABSSSI patients was 59.4 years. In 
Romania, 30,997 patients were included, and 70.3% (21,793) of these patients were severe 
(61.2% had a diagnosis of non-purulent ABSSSIs, and 38.8% had a diagnosis of purulent 
ABSSSIs). The Romanian patients were on average 10 years younger than the Italian patients 
(average age of 56.0 years among the non-purulent patients and 47.5 among the purulent 
patients). In the Spanish cohort, determining the accurate stratification by severity, 
infection type and characteristics of the patients was impossible. This issue was resolved by 
applying the Italian stratification of the ABSSSI patients to the Spanish population as 
described in the “Methods” section. In total, 17,997 ABSSSI patients were estimated, and 
78% (14,027) of the patients were considered to have severe infections (54% with a 
diagnosis of non-purulent ABSSSI and 46% with a diagnosis of purulent ABSSSI). 
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Table 3 - PSA results: length of stay (LoS) per patient 
 
On average, the dalbavancin treatment reduced the in-hospital length of stay by 4.15 days 
(95% CI: -4.57 to -3.74 days) per Italian ABSSSI patient, 2.5 days (95% CI: -2.78 to -2.23 days) 
per Romanian patient and 3.4 days (95% CI: -3.76 to -3.06) per Spanish patient (Table 3).  
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Table 4 - PSA results: annual costs (95% CI: Min-Max) 
 
Italy Romania Spain Italy  Romania Spain Italy  Romania Spain
Drugs € 5,37 € 5,77 € 2,88 € 10,82 € 13,50 € 9,28 € 5,45 € 7,73 € 6,41
(Min-Max) (€4.77-€6.01) (€5.24-€6.33) (€2.48-€3.3) (€9.7-€12) (€12.28-€14.79) (€8.27-€10.35) (€4.53 to €6.36) (€6.64 to €8.82) (€5.48 to €7.33)
Specialist service € 5,31 € 7,11 € 6,11 € 2,59 € 3,25 € 2,49 -€ 2,71 -€ 3,85 -€ 3,62
(Min-Max) (€4.6-€6.06) (€6.46-€7.79) (€5.39-€6.87) (€2.07-€3.17) (€2.87-€3.67) (€2.05-€2.97) (-€2.79 to -€2.13) (-€1.05 to -€0.73) (-€2.72 to -€2.01)
Hospitalization € 2,64 € 3,72 € 2,35 € 1,14 € 0,90 € 0,80 -€ 1,50 -€ 2,82 -€ 1,55
(Min-Max) (€2.17-€3.16) (€3.23-€4.24) (€1.94-€2.8) (€0.88-€1.44) (€0.72-€1.11) (€0.61-€1.02) (-€1.96 to -€1.05) (-€3.25 to -€2.39) (-€1.94 to -€1.17)
AE € 0,86 € 1,74 € 0,92 € 0,15 € 0,19 € 0,14 -€ 0,70 -€ 1,54 -€ 0,79
(Min-Max) (€0.76-€0.95) (€1.56-€1.91) (€0.82-€1.03) (€0.12-€0.18) (€0.16-€0.23) (€0.11-€0.16) (-€0.79 to -€0.62) (-€1.7 to -€1.39) (-€0.88 to -€0.7)
Total € 14,18 € 18,33 € 12,26 € 14,70 € 17,85 € 12,71 € 0,52 -€ 0,48 € 0,45
(Min-Max) (€12.7-€15.73) (€16.94-€19.79) (€10.98-€13.62) (€13.18-€16.3) (€16.37-€19.39) (€11.37-€14.12) (-€0.55 to €1.6) (-€1.61 to €0.65) (-€0.51 to €1.4)
Italy Romania Spain Italy  Romania Spain Italy  Romania Spain
Drugs € 3,42 € 2,33 € 2,78 € 7,70 € 4,54 € 6,36 € 4,28 € 2,21 € 3,58
(Min-Max) (€2.98-€3.89) (€1.99-€2.69) (€2.35-€3.25) (€6.79-€8.67) (€3.97-€5.15) (€5.58-€7.19) (€3.52 to €5.04) (€1.81 to €2.62) (€2.94 to €4.21)
Specialist service € 4,54 € 4,53 € 5,22 € 2,08 € 3,64 € 2,86 -€ 2,46 -€ 0,89 -€ 2,36
(Min-Max) (€3.91-€5.22) (€4.01-€5.09) (€4.55-€5.94) (€1.64-€2.58) (€3.2-€4.11) (€2.39-€3.38) (-€2.79 to -€2.13) (-€1.05 to -€0.73) (-€2.72 to -€2.01)
Hospitalization € 2,64 € 3,72 € 2,35 € 0,67 € 0,64 € 1,47 -€ 1,97 -€ 3,08 -€ 0,89
(Min-Max) (€2.17-€3.16) (€3.23-€4.24) (€1.94-€2.8) (€0.52-€0.85) (€0.52-€0.78) (€1.22-€1.73) (-€2.52 to -€1.42) (-€3.63 to -€2.52) (-€1.45 to -€0.33)
AE € 0,86 € 1,74 € 0,92 € 0,11 € 0,74 € 0,33 -€ 0,74 -€ 1,00 -€ 0,59
(Min-Max) (€0.76-€0.95) (€1.56-€1.91) (€0.82-€1.03) (€0.09-€0.14) (€0.63-€0.86) (€0.27-€0.4) (-€0.84 to -€0.64) (-€1.21 to -€0.78) (-€0.73 to -€0.46)
Total € 11,16 € 8,60 € 11,22 € 10,58 € 9,56 € 11,02 -€ 0,58 € 0,96 -€ 0,20
(Min-Max) (€9.9-€12.49) (€7.66-€9.6) (€9.94-€12.58) (€9.34-€11.89) (€8.55-€10.63) (€9.79-€12.32) (-€1.39 to €0.22) (€0.69 to €1.24) (-€0.74 to €0.34)
Italy Romania Spain Italy  Romania Spain Italy  Romania Spain
Drugs € 8,79 € 8,10 € 5,66 € 18,52 € 18,04 € 15,64 € 9,73 € 9,95 € 9,98
(Min-Max) (€8.14-€9.48) (€7.51-€8.72) (€5.03-€6.33) (€17.28-€19.81) (€16.84-€19.29) (€14.54-€16.78) (€8.35 to €11.11) (€8.71 to €11.18) (€8.77 to €11.2)
Specialist service € 9,85 € 11,64 € 11,33 € 4,67 € 6,90 € 5,35 -€ 5,17 -€ 4,74 -€ 5,98
(Min-Max) (€8.81-€10.95) (€10.87-€12.43) (€10.37-€12.34) (€3.8-€5.64) (€6.3-€7.52) (€4.6-€6.17) (-€5.67 to -€4.68) (-€5.17 to -€4.32) (-€6.52 to -€5.44)
Hospitalization € 5,09 € 4,45 € 4,72 € 1,81 € 1,55 € 2,27 -€ 3,27 -€ 2,91 -€ 2,45
(Min-Max) (€4.54-€5.67) (€3.98-€4.96) (€4.25-€5.21) (€1.52-€2.13) (€1.33-€1.77) (€1.98-€2.57) (-€3.82 to -€2.73) (-€3.34 to -€2.48) (-€2.86 to -€2.04)
AE € 1,60 € 2,74 € 1,77 € 0,27 € 0,93 € 0,47 -€ 1,34 -€ 1,81 -€ 1,30
(Min-Max) (€1.49-€1.72) (€2.53-€2.96) (€1.65-€1.9) (€0.23-€0.3) (€0.81-€1.05) (€0.4-€0.54) (-€1.44 to -€1.24) (-€1.97 to -€1.65) (-€1.41 to -€1.2)
Total € 25,33 € 26,93 € 23,48 € 25,28 € 27,42 € 23,73 -€ 0,06 € 0,48 € 0,25
(Min-Max) (€23.89-€26.82) (€25.76-€28.13) (€22.16-€24.84) (€23.67-€26.94) (€26.12-€28.74) (€22.37-€25.12) (-€1.73 to €1.61) (-€0.87 to €1.83) (-€1.15 to €1.64)
Difference dalbavancin - SoC
Nonpurulent ABSSSI patients (€ milions)
Cost Items
Cost Items
Purulent ABSSSI patients (€ milions)
SoC dalbavancin Difference dalbavancin - SoC
SoC dalbavancin
Cost Items
Total ABSSSI patients (€ milions)
SoC dalbavancin Difference dalbavancin - SoC
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The estimated budget impact of the new intervention (dalbavancin) by country and cost 
type (drug, hospitalization, specialist services and A&E) is reported in Table 4. From the Italian NHS 
perspective, a total expenditure of € 25.33 million (PSA 95% CI: € 23.89-26.82 million) was 
estimated and included in the analysis. The new intervention (dalbavancin) increased the drug cost 
by 37% compared to SoC. However, the incremental cost of the drug was completely offset by the 
decrease in resources required for the treatment (-38.5%), and the total impact was 
approximately neutral (-€ 0.06 million).  
In the Romanian setting, a total expenditure of € 26.9 million (PSA 95% CI: € 22.93-28.13 
million) was estimated for the treatment of all ABSSSI patients with SoC. Dalbavancin reduces the 
in-hospital length of stay by approximately 2.5 days (PSA 95% CI: -2.78 to -2.23 days) per patient 
(Table 4). The increase in the cost of the drugs (+37.1%) was partially compensated for by the 
decrease in the other costs (-35.1%). Compared to SoC, the total impact of the new intervention 
on the hospital budget was a negligible increase of 0.1% (€ 0.26 mill).  
From the Spain NHS perspective, the model estimated a total expenditure of € 23.5 million 
(95% CI: € 22.16-24.84 million) for the treatment of all ABSSSI patients with SoC. Dalbavancin 
reduces the in-hospital length of stay by approximately 3.2 days (PSA 95% CI: -3.76 to -3.06 days) 
per patient (Table 4). The increase in the cost of the drugs (+42.3%) was partially compensated for 
by the decrease in the other costs (-41.4%). Compared to SoC, the total impact of the new 
intervention on the hospital budget was a negligible increase of 1% (€ 0.25 million). 
The figure 3 shows the OWA results. In all three settings, the three most influential 
parameters were the assumptions considered for the daily cost of the hospital stay, the 
effectiveness estimated for dalbavancin and the cost of administration. If we consider the 
minimum cost in each country per hospitalization day (base-case analysis assuming the only DRG 
tariff is a unique cost parameter independent of the length of stay), dalbavancin could decrease 
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the total economic burden by several million euros in Italy, Romania and Spain. The efficacy of 
dalbavancin is the second most important parameter. 
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DISCUSSION 
Considering the costs from a hospital perspective (i.e., meals, laundry services, etc.), 
according to the probabilistic analysis, dalbavancin could decrease the total economic burden with 
a significant difference. 
The advantages of the dalbavancin administration scheme and currently reported 
tolerability data may be represented by the following: 
 Reduction in hospital LoS, and 
 Reduction in the following risks: 
  Peripherally inserted central catheter (PICC)-related adverse events—not necessary 
in the dalbavancin administration scheme, and 
 Reported drug-related adverse events compared to vancomycin. 
The reduction in the length of stay reduces the exposure to additional risk, such as Hospital 
Acquired Infections (HAIs), although these infections were not considered in the present analysis. 
In performing pharmacoeconomic evaluations, only the direct price of purchasing 
medications is customarily considered. However, to assess the total costs of intravenous (IV) drug 
therapy, other costs associated with preparation, administration and monitoring of IV antibiotic 
therapy must be evaluated. Gaining insight into all factors that contribute to the actual total 
overall costs of drug therapy may help increase awareness of the drivers of the costs of hospital 
services and identify opportunities for cost savings [34]. 
Hospital LoS is commonly considered by several authors the most important variable 
driving total healthcare costs in patients with different health conditions [35-37]; even if national 
healthcare providers usually pay hospitals through DRGs to standardize the financial contributions 
for the treatment of the same health conditions, over the threshold LoSs frequently occur due to 
adverse events, contributing to a further increase in the economic healthcare burden [38]. The 
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analysis presented in this manuscript predicted the possibility of an increased hospital LoS based 
on a statistical distribution of over a threshold analysis to enhance our understanding of how in-
dwelling can affect total healthcare costs in a DRG-based system. 
Intravenous drug infusion and catheter usage are important tools in in-hospital patient 
care but may be associated with serious catheter-related morbidity and discomfort. PICCs function 
as central catheters, allowing both drug infusion and blood sampling, and lessen the risk of central 
venous catheter insertion. Nevertheless, Periard and colleagues showed that even if PICCs are 
efficient and appreciated catheters in hospitalized patients, one-fifth of patients with PICC develop 
adverse events attributable to the inserted medical device, indicating that PICCs should not be 
used as the first-choice option in all hospitalized patients [39]. 
Vancomycin is active against Gram-positive bacteria, including MRSA, and is regularly used 
as an armamentarium for the treatment of ABSSSIs and other infectious diseases. The guidelines 
for vancomycin therapeutic monitoring by the IDSA suggest targeting vancomycin with 
concentrations of 10 mg/L to avoid the development of resistant strains and concentrations of 15-
20 mg/L to improve tissue penetration, which increases the probability of achieving optimal target 
serum concentrations and improving clinical outcomes. Nephrotoxicity, which is usually reversible, 
is the most serious common adverse effect of vancomycin and is strictly linked to its plasma 
concentrations. While the average daily cost of vancomycin is relatively low, a comprehensive 
account of the cost of vancomycin use should include the direct costs associated with measuring 
the serum concentrations and those associated with the treatment of adverse reactions, such as 
nephrotoxicity [40]. Dalbavancin has a better potential tolerability profile than other therapies for 
ABSSSIs, and it has been recommended by a recently published meta-analysis [41]. 
Although not within the scope of the present analysis, cross-bacterial colonization can 
increase with prolonged LoS and is mainly caused by MRSA. Clinicians should consider colonization 
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in assessments of discharging patients from the hospital, particularly if the clinical conditions are 
improved and stable [42, 43]. 
Common to most economic models, this study has various limitations, and we attempted 
to control these limitations. First, the model was constructed by combining data obtained from 
multiple randomized clinical trials involving homogeneous populations, but heterogeneous 
populations existed among the studies considered. To date, the lack of sufficient information for 
performing an adequate meta-analysis and the inability to appropriately compare the data 
prevent achieving better estimates. However, all clinical information and modelling assumptions 
were validated and discussed with key opinion leaders, who identified adequate uncertainty 
parameters that were used to perform the deterministic sensitivity analysis. 
Second, consulting with a panel of experts was the only way to identify the advantages 
associated with the dalbavancin treatment of patients suffering from ABSSSIs. However, for 
explanatory purposes, the constant rate of increases and decreases in the cost of items is based on 
scenarios designated by the panel of clinical experts. 
Moreover, in Italy and Spain, the tariffs can vary among the regions due to the 
delocalization of the NHS, but costs from only 1 region perspective were used, further limiting the 
analysis. Moreover, in Romania, hospitals purchase most antibiotic therapies directly from 
wholesalers, and the purchase price of dalbavancin used in the analysis was estimated. 
Additionally, assessment period for each country are not perfectly comparable due to the 
different data availability and the transition probabilities in Spain were assumed to be the same as 
those applied to Italy. However, all these limitations were considered in the deterministic and 
probabilistic SA. 
Finally, in the model, the cost of a 4-day LoS hospitalization was assumed to be the same as 
the cost of an 8-day LoS hospitalization. This assumption is a methodological limitation that has 
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negligible impact on the final estimates since it represents a cost item that is constant in both 
considered scenarios. 
The results of this analytic model are consistent with other published studies comparing 
SoC treatment for ABSSSIs with newer therapies, different therapeutic administration settings, 
such as outpatient parenteral antimicrobial therapy (OPAT), or avoiding PICC lines for treatment 
infusion. In a recent article, Browne, Muszbek [44] estimated the cost consequences of using 
daptomycin compared with those of using vancomycin as the first-line treatment in patients with 
proven MRSA-induced bacteraemia-infective endocarditis. Daptomycin required fewer therapeutic 
switches and a shorter length of stay. When the length of stay was reduced from 42 days to 28 
days, daptomycin saved £ 4037 per person compared with vancomycin. Stephens, Gao [45] 
compared the cost of oral linezolid therapy with the cost of vancomycin or daptomycin regimens 
and concluded that using linezolid has a potential economic benefit over traditional OPAT 
considering the total inpatient and outpatient medical costs. PICCs are commonly used to 
administer antibiotics or other medications, particularly in patients requiring hospital in-dwelling; 
in a study evaluating the cost offsets of treating Gram-positive ABSSSIs with varied hospital LoSs, a 
sensitivity analysis comparing the inpatient and outpatient cost breakdown revealed that a key 
outpatient cost driver was the PICC cost, with an average per patient cost of $873 for placement 
and $205 for complications [46]. 
 
CONCLUSION 
This economic analysis suggests that the use of dalbavancin could generate a significant 
reduction in the length of stay with no statistically significant incremental costs from a National 
healthcare provider perspective. The validity of this conclusion should better be tested in a “real-
life” setting, though, it has been further strengthen by the convergence of the results reported 
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from all three European Countries with different discharge probabilities, cost inputs and budget 
constraints. In conclusion, the use of dalbavancin would allow an early discharge approach in 
ABSSSI management, providing the option to significantly reduce patients’ exposure to additional 
risks associated with prolonged hospitalisation at no incremental cost for the National healthcare 
providers. This model could represent a useful tool for clinicians and policy makers to inform their 
decision about optimal treatment pattern of ABSSSIs in the hospital setting. 
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FIGURE LEGENDS 
Fig. 1 Decision tree model structure 
Fig. 2 Average annual admissions due to severity and presence of purulence in Italy (2006-2010), 
Romania (2010-2013), and Spain (2006-2015) 
* Assumed to have the same distribution as the Italian data 
Fig. 3 DSA: tornado diagram (total burden) 
 
